{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=5",
    "query": {
      "intervention": "Glucagon-Like Peptide-1 Agonist (GLP-1)",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 177,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-Like+Peptide-1+Agonist+%28GLP-1%29&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T15:42:48.644Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06732245",
      "title": "Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity and Overweight"
      ],
      "interventions": [
        {
          "name": "NA-931",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "NA-931 150 mg + no Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 224,
      "start_date": "2026-08-15",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06732245"
    },
    {
      "nct_id": "NCT07032311",
      "title": "Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Liver Disease"
      ],
      "interventions": [
        {
          "name": "Behavioral Treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "SIPPA Solutions INC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2026-08-20",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 1,
      "location_summary": "Jamaica, New York",
      "locations": [
        {
          "city": "Jamaica",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07032311"
    },
    {
      "nct_id": "NCT06068946",
      "title": "VK2735 for Weight Management Phase 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Weight Loss"
      ],
      "interventions": [
        {
          "name": "VK2735",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Viking Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2023-08-31",
      "completion_date": "2024-04-02",
      "has_results": false,
      "last_update_posted_date": "2025-02-12",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06068946"
    },
    {
      "nct_id": "NCT06877572",
      "title": "Weight Loss Management in Endometrial Cancer Survivors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Endometrial Cancer Survivors",
        "Weight Management",
        "Early Stage Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Weight loss with pharmacotherapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Weight loss without pharmacotherapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-03-25",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06877572"
    },
    {
      "nct_id": "NCT07611201",
      "title": "The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Overweight",
        "Taste Perception",
        "Olfaction",
        "Eating Behavior",
        "Appetite"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Purdue University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2025-02-20",
      "completion_date": "2026-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 1,
      "location_summary": "West Lafayette, Indiana",
      "locations": [
        {
          "city": "West Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07611201"
    },
    {
      "nct_id": "NCT05260021",
      "title": "A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type2 Diabetes",
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "T2D",
        "T2DM (Type 2 Diabetes Mellitus)",
        "Glucose Metabolism Disorders",
        "Endocrine System Diseases",
        "Metabolic Disease"
      ],
      "interventions": [
        {
          "name": "Tirzepatide Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 99,
      "start_date": "2022-04-13",
      "completion_date": "2025-01-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05260021"
    },
    {
      "nct_id": "NCT07226947",
      "title": "Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Body Composition"
      ],
      "interventions": [
        {
          "name": "Smartwatch activity and body composition monitor",
          "type": "DEVICE"
        },
        {
          "name": "General guidance on recommended exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-11-24",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07226947"
    },
    {
      "nct_id": "NCT03492580",
      "title": "A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like Peptide-1 (GLP-1) Agonist",
          "type": "DRUG"
        },
        {
          "name": "Anti-hyperglycemic Agents (AHA)",
          "type": "DRUG"
        },
        {
          "name": "Thiazolidinediones (TZD)",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylureas (SU)",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 714582,
      "start_date": "2018-02-22",
      "completion_date": "2018-06-25",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492580"
    },
    {
      "nct_id": "NCT06584916",
      "title": "A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Orforglipron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 376,
      "start_date": "2024-09-13",
      "completion_date": "2025-11-21",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pelham",
          "state": "Alabama"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06584916"
    },
    {
      "nct_id": "NCT07107334",
      "title": "A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrioid Endometrial Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Glucagon-like peptide 1 receptor agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2026-04-07",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-10-13T15:42:48.644Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07107334"
    }
  ]
}